Clarithromycin Prophylaxis in Preterm Infants Colonisation With Ureaplasma Urealyticum and Mycoplasma Hominis
NCT ID: NCT01652118
Last Updated: 2012-07-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
250 participants
INTERVENTIONAL
2011-10-31
2013-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The investigators aimed with this treatment, the bronchopulmonary dysplasia rate of preterm babies may decrease.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Clarithromycin
Fist group treated with clarithromycin which is include 10 days application.
clarithromycin treatment for prophylaxis of bronchopulmonary dysplasia
placebo
Second group treated with salin as same as amount of clarithromycine volume
Saline
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
clarithromycin treatment for prophylaxis of bronchopulmonary dysplasia
Saline
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* CardiaC abnormality,
* without inform consent
1 Hour
2 Days
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zekai Tahir Burak Women's Health Research and Education Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sadik Yurttutan
Fellowship of neonatology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ugur Dilmen, Prof. Dr.
Role: STUDY_DIRECTOR
Zekai Tahir Burak Women's Health Research and Education Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zekai Tahir Burak Maternity Teaching Hospital
Ankara, Middle Anatolia, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Sadık Yurttutan, M.D
Role: primary
Fuat Emre Canpolat, M.D.
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
05059079727
Identifier Type: -
Identifier Source: org_study_id